Relmada Therapeutics IncNASDAQ:RLMD
- LAST PRICE3.0000
- TODAY'S CHANGE (%)-0.1600 (-5.0633%)
- Bid / Lots3.0000/ 7
- Ask / Lots3.0300/ 7
- Open / Previous Close3.1400 / 3.1600
- Day Range
- 52 Week Range
- Volume76,091
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RLMD |
|---|---|---|
| 09:32 ET | 1017 | 3.14 |
| 09:35 ET | 100 | 3.25 |
| 09:37 ET | 100 | 3.25 |
| 09:42 ET | 600 | 3.17 |
| 09:44 ET | 1770 | 3.18 |
| 09:46 ET | 767 | 3.19 |
| 09:48 ET | 200 | 3.23 |
| 09:50 ET | 300 | 3.1033 |
| 09:51 ET | 1000 | 3.0901 |
| 09:53 ET | 100 | 3.225 |
| 09:55 ET | 100 | 3.22 |
| 09:57 ET | 2100 | 3.18 |
| 10:02 ET | 300 | 3.14 |
| 10:04 ET | 100 | 3.18 |
| 10:06 ET | 100 | 3.18 |
| 10:08 ET | 100 | 3.175 |
| 10:09 ET | 3364 | 3.12 |
| 10:11 ET | 200 | 3.13 |
| 10:13 ET | 300 | 3.1725 |
| 10:15 ET | 100 | 3.1299 |
| 10:18 ET | 500 | 3.18 |
| 10:22 ET | 100 | 3.18 |
| 10:26 ET | 2020 | 3.0987 |
| 10:27 ET | 100 | 3.125 |
| 10:29 ET | 200 | 3.125 |
| 10:31 ET | 452 | 3.09 |
| 10:33 ET | 376 | 3.1 |
| 10:38 ET | 213 | 3.07 |
| 10:40 ET | 1000 | 3.06 |
| 10:42 ET | 263 | 3.0547 |
| 10:44 ET | 100 | 3.045 |
| 10:45 ET | 200 | 3.0501 |
| 10:47 ET | 200 | 3.045 |
| 10:49 ET | 300 | 3.045 |
| 10:54 ET | 2085 | 3.025 |
| 10:56 ET | 100 | 3.025 |
| 10:58 ET | 100 | 3.025 |
| 11:07 ET | 700 | 3.0675 |
| 11:09 ET | 200 | 3.05 |
| 11:12 ET | 361 | 3.03 |
| 11:16 ET | 100 | 3.04 |
| 11:18 ET | 100 | 3.04 |
| 11:20 ET | 1973 | 3.07 |
| 11:21 ET | 100 | 3.07 |
| 11:23 ET | 100 | 3.07 |
| 11:30 ET | 1814 | 3.02 |
| 11:32 ET | 8957 | 3.015 |
| 11:34 ET | 6930 | 3.01 |
| 11:36 ET | 300 | 3.02 |
| 11:38 ET | 100 | 3.01 |
| 11:41 ET | 600 | 3.01 |
| 11:45 ET | 15265 | 3 |
| 11:48 ET | 2910 | 3.01 |
| 11:50 ET | 600 | 3.02 |
| 11:52 ET | 300 | 3.03 |
| 11:54 ET | 300 | 3.02 |
| 11:57 ET | 100 | 3.01 |
| 11:59 ET | 100 | 3.01 |
| 12:01 ET | 200 | 3 |
| 12:03 ET | 300 | 3 |
Yesterday
Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease, from 7:30AM ET on Thursday Nov 14, 2024 by Dow Jones
7:30AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 7, 2024
Press Release: Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update, from 4:32PM ET on Thursday Nov 07, 2024 by Dow Jones
4:32PM ET on Thursday Nov 07, 2024 by Dow JonesRelmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update, from 4:10PM ET on Thursday Nov 07, 2024 by Dow Jones
4:10PM ET on Thursday Nov 07, 2024 by Dow JonesPress Release: Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update, from 4:10PM ET on Thursday Nov 07, 2024 by Dow Jones
4:10PM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 4, 2024
Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024, from 4:30PM ET on Monday Nov 04, 2024 by Dow Jones
4:30PM ET on Monday Nov 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Relmada Therapeutics Inc | 95.4M | -1.0x | --- |
Genenta Science SPA | 89.4M | -9.8x | --- |
Annovis Bio Inc | 96.2M | -1.8x | --- |
Monopar Therapeutics Inc | 96.2M | -9.3x | --- |
Invivyd Inc | 94.4M | -0.4x | --- |
Renovaro Inc | 94.4M | -0.7x | --- |
Company Information
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.
Contact Information
- Headquarters
- 2222 Ponce De Leon Blvd. 3Rd FloorCORAL GABLES, FL, United States 33134
- Phone
- 646-876-3459
- Fax
- ---
Executives
- Independent Chairman of the Board
- Charles Casamento
- Chief Executive Officer, Director
- Sergio Traversa
- Chief Financial Officer
- Maged Shenouda
- Chief Accounting, Compliance Officer
- Charles Ence
- Acting Chief Scientific Officer
- Paolo Manfredi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $95.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 30.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.37 |
EPS | $-2.87 |
Book Value | $2.84 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
